Research topics
Immunoediting, epigenetic regulations in tumour immunology, HPV16-associated tumours, immunotherapy of MHC class I-positive and -deficient tumours, gene and cell immunotherapy, minimal residual tumour disease.
Current grant support
Grant Agency of the Czech Republic (grants Nos.: 301/07/1410, 301/09/1024, 301/10/2174)
Clinigene Network of Excellence for the Advancement of Gene Transfer and Therapy EU-FP6 Project No. 0189337)
The Internal Agency of Ministry od Health of the Czech republic (grant No.: NS10660-3)
Most important recent papers
(2006-present; names of the lab members underlined)Reinis M, Simova J, Bubenik J. Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours. Int J Cancer 118(7): 1836-42, 2006. (Pubmed) (DOI)
Indrova M, Bieblova J, Jandlova T, Vonka V, Pajtasz-Piasecka E, Reinis M. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours. Int J Oncol 28(1): 253-9, 2006. (Pubmed)
Simova J, Bubenik J, Bieblova J, Rosalia RA, Fric J, Reinis M. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours. Int J Oncol 29(6): 1567-71, 2006. (Pubmed)
Reinis M, Weiser B, Kuiken C, Dong T, Lang D, Nachman S, Zhang Y, Rowland-Jones S, Burger H. Genomic analysis of HIV type 1 strains derived from a mother and child pair of long-term nonprogressors. AIDS Res Hum Retroviruses 23(2): 309-15, 2007. (Pubmed) (DOI)
Reinis M, Simova J, Indrova M, Bieblova J, Pribylova H, Moravcova S, Jandlova T, Bubenik J. Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours. Int J Oncol 30(4): 1011-7, 2007. (Pubmed)
Reinis M, Simova J, Indrova M, Bieblova J, Bubenik J. CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours. Int J Oncol 30(5): 1247-51, 2007. (Pubmed)
Indrova M, Bieblova J, Bubenik J, Reinis M. IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int J Oncol 32(2): 499-507, 2008. (Pubmed)
Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, Simova J, Jandlova T, Bubenik J, Reinis M. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 123(2): 218-27, 2008. (Pubmed) (DOI)
Indrova M, Bieblova J, Rossowska J, Kuropka P, Pajtasz-Piasecka E, Bubenik J, Reinis M. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int J Oncol 34(1): 173-9, 2009. (Pubmed)
Kemal KS, Reinis M, Weiser B, Burger H. Methods for viral RNA isolation and PCR amplification for sequencing of near full-length HIV-1 genomes. Methods Mol Biol 485: 3-14, 2009. (Pubmed) (DOI)
Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M, Bubenik J. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int J Oncol 36(3): 545-51, 2010. (Pubmed)
Simova J, Indrova M, Bieblova J, Mikyskova R, Bubenik J, Reinis M. Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy. Int J Cancer 126(12): 2997-3004, 2010. (Pubmed) (DOI)
Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M, Bubenik J. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int J Oncol 36(3): 545-51, 2010. (Pubmed)
Nussbaumerova M, Srp J, Masa M, Hradilek M, Sanda M, Reinis M, Horn M, Mares M. Single- and double-headed chemical probes for detection of active cathepsin D in a cancer cell proteome. Chembiochem 11(11): 1538-41, 2010. (Pubmed) (DOI)
Indrova M, Simova J, Bieblova J, Bubenik J, Reinis M. NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours. Oncol Rep 25(1): 281-8, 2011. (Pubmed)
Mikyskova R, Indrova M, Simova J, Bieblova J, Bubenik J, Reinis M. Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine. Oncol Rep 25(6): 1683-9, 2011. (Pubmed) (DOI)
Reviews
Niederhafner P, Reinis M, Sebestik J, Jezek J. Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J Pept Sci 14(5): 556-87, 2008. (Pubmed) (DOI)
Reinis M. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas. Curr Opin Mol Ther 10(5): 526-34, 2008. (Pubmed)
Bubenik J. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours. Curr Cancer Drug Targets 8(3): 180-6, 2008. (Pubmed)
Reinis M. Immunotherapy of MHC class I-deficient tumors. Future Oncol 6(10): 1577-89, 2010. (Pubmed) (DOI)